Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021

SELL
$6.21 - $48.36 $72,414 - $563,925
-11,661 Closed
0 $0
Q3 2020

Oct 30, 2020

BUY
$7.21 - $9.37 $2,372 - $3,082
329 Added 2.9%
11,661 $89,000
Q2 2020

Aug 05, 2020

BUY
$3.11 - $9.27 $35,242 - $105,047
11,332 New
11,332 $95,000

About Aptevo Therapeutics Inc.


  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $22.4M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.